LU99_CLYBL-bxb-v2
LUMCi004-A-2
General
Cell Line |
|
hPSCreg name | LUMCi004-A-2 |
Cite as: | LUMCi004-A-2 (RRID:CVCL_C6UD) |
Alternative name(s) |
LU99_CLYBL-bxb-v2
|
Cell line type | Human induced pluripotent stem cell (hiPSC) |
Similar lines |
LUMCi004-A (LUMC0099iCTRL04) LUMCi004-A-1 (LU99_AAVS1-bxb-v2) LUMCi004-B (LUMC0030iCTRL12) LUMCi004-C (LUMC0031iCTRL08) |
Last update | 28th November 2022 |
User feedback | |
Provider |
|
Generator |
Leiden University Medical Center (LUMC)
Contact:
LUMC hiPSC core facility |
Owner | LUMC hiPSC core facility |
Distributors | |
Derivation country | Netherlands |
External Databases |
|
BioSamples | SAMEA112164541 |
Cellosaurus | CVCL_C6UD |
Wikidata | Q117704635 |
General Information |
|
Publications | |
* Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
Subclone of |
Donor Information
General Donor Information |
|
Sex | female |
Ethnicity | caucasian |
Phenotype and Disease related information (Donor) |
|
Diseases | No disease was diagnosed.
|
Family history | No |
Is the medical history available upon request? | No |
Is clinical information available? | No |
Other Genotyping (Donor) |
|
Is there genome-wide genotyping or functional data available? |
No
|
Donor Relations |
|
Other cell lines of this donor | |
External Databases (Donor) |
|
BioSamples | SAMEA5032583 |
Ethics
Also have a look at the ethics information for the parental line
LUMCi004-A
.
Is there an MTA available for the cell line? | Yes |
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | |
Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | No |
hIPSC Derivation
General |
|
The source cell information can be found in the parental cell line
LUMCi004-A.
|
|
Reprogramming method |
|
Vector type | None |
Vector free reprogramming |
|
Type of used vector free reprogramming factor(s) |
mRNA
|
Other |
|
Derived under xeno-free conditions |
Unknown |
Derived under GMP? |
No |
Available as clinical grade? |
No |
Culture Conditions
Surface coating | Laminin |
Feeder cells |
No |
Passage method |
Enzymatically
TrypLE
|
O2 Concentration | 20 % |
CO2 Concentration | 5 % |
Medium |
Other medium:
Base medium: StemFlex
Main protein source: Fetal bovine serum Serum concentration: % |
Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | No |
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | No |
Characterisation
Differentiation Potency
Microbiology / Virus Screening |
|
Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
Yes
Normal, 46, XX
Passage number: P10
|
Other Genotyping (Cell Line) |
Genetic Modification
Genetic modifications not related to a disease |
|
Login to share your feedback, experiences or results with the research community.